Adaptive Biotechnologies Corporation cash flow to debt ratio of -16.39% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Adaptive Biotechnologies Corporation's free cash flow has increased -50.50% from $-98.88M last year to $-48.95M, signaling increasing performance

Adaptive Biotechnologies Corporation's debt to equity ratio is 0.96, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Adaptive Biotechnologies Corporation's debt has increased relative to shareholder equity from 0.44 last year to 0.96 today, signaling weakened financials

Adaptive Biotechnologies Corporation has negative EBITDA, making leverage ratio unreliable

Adaptive Biotechnologies Corporation's interest coverage ratio is -3.97, which means that the company struggles to meet interest obligations, signaling financial risk.

Adaptive Biotechnologies Corporation's profit margin has increased (-81.13%) in the last year from -89.12% to -16.82%, signaling increasing performance

Adaptive Biotechnologies Corporation's short-term assets of $300.19M exceed its short-term liabilities of $89.92M

Adaptive Biotechnologies Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Adaptive Biotechnologies Corporation's return on equity of -24.26%, is lower than 15.00%, indicating bad performance

Adaptive Biotechnologies Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Adaptive Biotechnologies Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Adaptive Biotechnologies Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Adaptive Biotechnologies Corporation has negative free cash flow, indicating cash burn

Adaptive Biotechnologies Corporation's yearly earnings has increased -62.69% since last year from $-159.49M to $-59.50M, signaling increasing performance

Adaptive Biotechnologies Corporation's yearly revenue has increased 54.77% since last year from $178.96M to $276.98M, signaling increasing performance

ROIC -10.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Adaptive Biotechnologies Corporation's 3-year revenue CAGR of 14.34% is positive, indicating growing revenue over the past 3 years

Adaptive Biotechnologies Corporation had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Adaptive Biotechnologies Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Adaptive Biotechnologies Corporation has insufficient data to evaluate this check.

Adaptive Biotechnologies Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Adaptive Biotechnologies Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Adaptive Biotechnologies Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Adaptive Biotechnologies Corporation has insufficient data to evaluate this check.

Adaptive Biotechnologies Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Adaptive Biotechnologies Corporation has a price-to-book ratio of 15.07x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Adaptive Biotechnologies Corporation has a price-to-sales ratio of 11.36x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue